# Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

> **NCT04006262** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 32 (estimated)

## Conditions studied

- Localized Oesogastric Adenocarcimona
- MSI and or dMMR

## Interventions

- **DRUG:** Nivolumab 10 MG/ML
- **DRUG:** Ipilimumab 200 MG in 40 ML Injection

## Key facts

- **NCT ID:** NCT04006262
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-23
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006262, "Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04006262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*